Latest Breaking News On - முழங்கால் ஆஸ்டியோவார்த்ரைடிஸ் - Page 2 : comparemela.com
Knee Osteoarthritis Market Size, Future Growth, Demand, Share, Predicted to Grow By 2021 With Compet
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Rising Number of Osteoporosis Cases Boosts Demand Avenues in Viscosupplementation Market, says Transparency Market Research
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
The steroid 19-nortestosterone (nandrolone, 19-NT), popularized in esterified form as nandrolone decanoate (ND, Deca-durabolin or simply “Deca”), is an injectable synthetic anabolic-androgenic steroid (AAS) used in the strength and fitness community for building muscle. The traditional stack, hailed by “bro science” for over 40 years, combines ND with a testosterone ester such as testosterone cypionate or testosterone enanthate. The objective of the combination is to maximize the anabolic effects while keeping the adverse effects of supraphysiological use in check. ND and its relative safety as an anabolic agent has been addressed in the clinical context (48, 49) and for non-medical (i.e., athletic performance or cosmetic) use (see, e.g., past
Share this article
Share this article
HONG KONG, June 10, 2021 /PRNewswire/ CBMG Holdings (or the Company ), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced early promising safety and efficacy results of C-CAR066, a novel second generation chimeric antigen receptor T (CAR-T) therapy targeting CD20 antigen in relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) that has failed to an anti-CD19 CAR-T therapy. Patients who fail anti-CD19 CAR-T therapy generally have a dismal prognosis and are an important group with high unmet medical needs. This abstract was recently presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting by the Principal Investigator (PI) of the study, Aibin Liang, M.D., Professor of Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, China.
Share this article
Share this article
HONG KONG, June 10, 2021 /PRNewswire/ CBMG Holdings (or the Company ), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced updated clinical data for C-CAR039, a novel CD19/CD20 bi-specific CAR-T cell product in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL). This work was presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, by the Principal Investigator (PI) of the study, Aibin Liang, M.D., Professor of Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine.
Additionally, the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted the Company an orphan drug designation (ODD) to C-CAR039, for the treatment of follicular lymphoma, an indolent form of Non-Hodgkin s Lymphoma.
vimarsana © 2020. All Rights Reserved.